论文信息 - THE ROLE OF LIGANDS OF ACTIVATORY RECEPTOR NKG2D IN THE IMMUNE-DEPENDENT PATHOGENESIS AND EVOLUTION OF INFLAMMATORY BOWEL DISEASE (IBD)

THE ROLE OF LIGANDS OF ACTIVATORY RECEPTOR NKG2D IN THE IMMUNE-DEPENDENT PATHOGENESIS AND EVOLUTION OF INFLAMMATORY BOWEL DISEASE (IBD)

REFERENCES 1. Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross J8, Miller VA, Lim D, Amanam l, Chao J, Catenacci D, Cho M, Braiteh 7, Klempner SJ, Ali 8M, Fakih M. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSl-high metastatic colorectal cancer. Ann Oncol 2019;30(7):1096–1103 2. Overman MJ, et al. Durable Clinical/Benefit With Nivolumab Plus lpilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. Clin Oncol 2018;36(8):773–779.

[1] James R. Anderson,et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. , 2019, The Lancet. Oncology.

[2] E. Sokol,et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. , 2019 .

[3] M. Sawyer,et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4] P. O'dwyer,et al. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies , 2017, Clinical Cancer Research.

[5] D. Munn,et al. IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. , 2016, Trends in immunology.